Home » Business News » 2011 » March » March 15, 2011

Crucell Intends to Delist Ordinary Shares on NYSE Euronext

March 15, 2011 - LEIDEN, NETHERLANDS

Dutch biopharmaceutical companyCrucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announcedthat it has obtained the approval of Euronext Amsterdam N.V. toterminate thelisting of its ordinary shares (Ordinary Shares) on NYSE Euronext inAmsterdam(NYSE Euronext).

The termination of the listing of Ordinary Shares on NYSE Euronext wasapprovedby Euronext Amsterdam N.V. and will occur on 12 April 2011. The lasttrading daywill be 11 April 2011.

As of the time of delisting from NYSE Euronext, the following codeswill nolonger be applicable to Crucell N.V. (Crucell): symbol "CRXL": EuronextcodeNL0000358562, ISIN: NL0000358562.

Crucell intends to delist the Ordinary Shares from the Swiss Exchange(SIX)simultaneously with the delisting from NYSE Euronext.

As previously announced on 8 March 2011, to effect the delisting of theAmericanDepositary Shares (ADSs) from the NASDAQ Global Market Select (NASDAQ),Crucellintends to file a Form 25 with the U.S. Securities and ExchangeCommission(SEC). Crucell intends to file a Form 15F with the SEC toderegister andterminate its reporting obligations under the U.S. Securities ExchangeAct of1934, as amended. The filing of the Form 15F will precede the delistingof theOrdinary Shares from NYSE Euronext and SIX.

Crucell reserves the right to delay or withdraw for any reason the filingof theForm 25 and Form 15F or the delisting on NYSE Euronext and/or SIX.

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) is a globalbiopharmaceutical company focused on research development, production andmarketing of vaccines, proteins and antibodies that prevent and/or treatinfectious diseases. In 2010 alone, Crucell distributed more than 105millionvaccine doses in more than 100 countries around the world. Crucell is oneof themajor suppliers of vaccines to UNICEF and the developing world. Crucell wasthefirst manufacturer to launch a fully-liquid pentavalent vaccine. CalledQuinvaxem®, this innovative combination vaccine protects against fiveimportantchildhood diseases. Over 180 million doses have been sold since its launchin2006 in more than 50 GAVI countries. With this innovation, Crucell hasbecome amajor partner in protecting children in developing countries. Otherproducts inCrucell's core portfolio include a vaccine against Hepatitis B and avirosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines,suchas an oral anti-typhoid vaccine, an oral cholera vaccine and the onlyaluminum-free Hepatitis A vaccine on the market. Crucell has a broad developmentpipeline, with several product candidates based on its unique PER.C6®productiontechnology. Crucell licenses its PER.C6® technology and othertechnologies tothe biopharmaceutical industry. Important partners and licensees includeJohnson& Johnson, DSM Biologics, sanofi-aventis, Novartis, Pfizer/Wyeth, GSK, CSLandMerck & Co. Crucell is headquartered in Leiden, the Netherlands, withoffices inChina, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK,theUSA and Vietnam. Crucell employs over 1300 people. For more information,pleasevisit

Forward-looking statements

This press release contains forward-looking statements that involveinherentrisks and uncertainties. We have identified a number of important factorsthatmay cause actual results to differ materially from those contained in suchforward-looking statements. For information relating to these factorspleaserefer to our Form 20-F, as filed with the US Securities and ExchangeCommissionon April 7, 2010, in the section entitled 'Risk Factors' and in our secondquarter 2010 financial results, as filed with the Securities and ExchangeCommission on August 17, 2010 in the section entitled 'Risk Paragraph'. TheCompany prepares its financial statements under International FinancialReporting Standards (IFRS).

PDF file:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Crucell N.V. via Thomson Reuters ONE


For further information please contact:
Oya Yavuz
Vice President Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
Email Contact


Comment on this story